// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Gastrointestinal involvement in spondyloarthritis is not all ibd: increased risk of diverticulitis with longer disease duration in the asas-comospa cohort

M.H. Derakhshan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Spondyloarthritis

N/A

Gene enhancers associated with an increased risk of developing jia fail to down regulate runx1 after cell stimulation

A. Yarwood - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Genomic dissection of immune-mediated disease: prognosis, vasculitis and eosinophils

K.G. Smith - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

N/A

Glucosepane : a new biomarker of the severity of osteoarthritis

N. Rabbani - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Interleukin

Gout is associated with an increased risk of cancer – a nationwide cohort study including over 70,000 gout patients

K. Zobbe - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

N/A

Guideline-based care improves outcomes that matter to patients: tighter control, less suffering, and greater well-being over the past decade in canadian ra patients

S. J. Bartlett - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Guidelines for juvenile idiopathic arthritis management: is there a room for combined methotrexate and leflunomide therapy in the treatment recommendations

Y. Atef - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Health care resource utilisation (HCRU and cost analyses of systemic lupus erythematosus (SLE as a function of disease severity: analysis of real-world claims data from a german sickness fund

E.R. Hammond - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

V. Strand - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Giant cell arteritis

Tocilizumab

High disease activity and disability at one year in two clusters of patients with rheumatoid arthritis defining themselves as in an acceptable state at treatment initiation

J. Gwinnutt - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Hip shape predicts knee osteoarthritis outcomes over a decade in older-adults

I.P. Munugoda - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

N/A

Histological and serological characteristics contribute to divergent outcomes for indigenous patients with lupus nephritis

J. Nossent - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

N/A

Hospital admission trends and short-term outcome for iga vasculitis in children and adults in western australia

J. Nossent - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Henoch-Schonlein purpura nephritis

N/A

How big data and machine learning could change the game

S. Khalid - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

How effective are interventions targeting patient activation in people with long term physical conditions? a systematic review

B. Jones - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

How effective is postgraduate training in the rheumatology department of a teaching hospital?

A. Paul - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

How money should be spent: patients perspectives on scleroderma research funding

S. Divani - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Iloprost

How to distinguish the major capillaroscopic patterns

A.L. Herrick - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

How to perform a quick and reliable physical examination in rheumatology

M. Doherty - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

How to use mri in the diagnosis and management of osteoarthritis

P.G. Conaghan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Copyright © 2026. QuantiNova All rights reserved